FIELD: medicine, pharmaceutics.
SUBSTANCE: the suggested pharmaceutical composition contains 2-ethylthiobenzimidasol hydrobromide at efficient quantity and a pharmaceutically acceptable carrier. Method for preventing and treating chronic fatigue syndrome should be fulfilled due to introducing the mentioned pharmaceutical composition at its daily dosage of 250-1500 mg for 5-20 d to provide the chance for repeating the course of therapy after an interval of 5 d or more. While treating chronic fatigue syndrome one should additionally apply cavinton, adenosine triphosphate, vitamins, cibazone, mesapam to realize the mentioned indication.
EFFECT: higher efficiency.
4 cl, 6 ex, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION FOR TREATING ASTHENIA AND/OR CHRONIC FATIGUE SYNDROME | 2014 |
|
RU2578412C1 |
| INJECTABLE DOSAGE FORM FOR TREATMENT OF PARKINSON'S DISEASE, METHOD FOR PREPARING AND USING IT | 2011 |
|
RU2520758C2 |
| NEW COMBINATIONS OF NERAMEXANE FOR TREATING NEURODEGENERATIVE DISORDERS | 2008 |
|
RU2432161C1 |
| ADAMANTYL DERIVATIVES OF BENZIMIDAZOLE, HAVING ANTIPARKINSONIAN ACTIVITY | 2023 |
|
RU2820315C1 |
| GSK-3 INHIBITORS | 2006 |
|
RU2449998C2 |
| NEW 1,4-DIAZA-BICYCLO[3,2,2]NONYL-OXADIAZOLYL DERIVATIVES AND THEIR MEDICAL APPLICATION | 2007 |
|
RU2427581C2 |
| PHARMACEUTICAL COMBINATION INFLUENCING CENTRAL NERVOUS SYSTEM FUNCTION; METHOD OF CORRECTING CONDITIONS ASSOCIATED WITH DYSFUNCTION OF CENTRAL NERVOUS SYSTEM; PHARMACEUTICAL KIT; AGENT ASSISTING THERAPEUTICAL SUBSTANCES AND METABOLITES TO CROSS BLOOD-BRAIN BARRIER; AND ENDONASAL DRUG | 2004 |
|
RU2253461C1 |
| SIMULTANEOUS, SEPARATE OR SEPARATED IN TIME THERAPEUTIC APPLICATION OF, AT LEAST, ONE BOTULIC NEUROTOXIN AND, AT LEAST, ONE OPIATE DERIVATIVE | 2007 |
|
RU2434637C2 |
| PEPTIDE WITH NEUROPROTECTIVE ACTIVITY ON MODEL OF MFTP-INDUCED PARKINSONISM AND A PHARMACEUTICAL COMPOSITION ON ITS BASIS | 2017 |
|
RU2662429C1 |
| [1,2,4]-DITHIAZOLI(DI)NE DERIVATIVES, GLUTATHIONE-S-TRANSFERASE AND NADPH: QUINONE-OXIDOREDUCTASE FOR PREVENTION AND TREATMENT OF UNFAVOURABLE STATES ASSOCIATED WITH CYTOTOXICITY IN WHOLE AND APOPTOSIS PARTICULARLY | 2006 |
|
RU2397162C2 |
